Comment
doi: 10.1136/ebmed-2017-110726.
Epub 2017 Aug 11.
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids
Affiliations
- PMID: 28801320
- DOI: 10.1136/ebmed-2017-110726
Item in Clipboard
Comment
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids
Evid Based Med.
2017 Oct.
No abstract available
Conflict of interest statement
Competing interests: MC and PR are consultants and/or members of the Speaker Bureau at AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and Novartis.
Comment on
-
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2017 Feb 10;2(2):CD012066. doi: 10.1002/14651858.CD012066.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Jun 5;6:CD012066. doi: 10.1002/14651858.CD012066.pub3. PMID: 28185242 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
